Review anchor
RAC-alpha serine/threonine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
RAC-alpha serine/threonine-protein kinase
CHEMBL4282
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RAC-alpha serine/threonine-protein kinase as ChEMBL target CHEMBL4282, mapped to UniProt P31749. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4282
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31749
RAC-alpha serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why RAC-alpha serine/threonine-protein kinase matters
RAC-alpha serine/threonine-protein kinase is reviewed as RAC-alpha serine/threonine-protein kinase (UniProt P31749); RAC-alpha serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 7395 compounds, and 1631 assays, with lead potency reaching pChEMBL 10.7.
Protein context
RAC-alpha serine/threonine-protein kinase
RAC-alpha serine/threonine-protein kinase Sequence length is 480 aa.
Review this target as RAC-alpha serine/threonine-protein kinase, mapped to UniProt P31749. Sequence length is 480 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P31749
Protein
Disease context
neoplasm
RAC-alpha serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm. 2 linked drugs keep the rationale reviewable. Linked drugs include BAY-1125976, RUPITASERTIB.
Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BAY-1125976, RUPITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 7395 compounds, and 1631 assays for this target. The dominant activity type is IC50. CHEMBL5407182 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL5407182 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why RAC-alpha serine/threonine-protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31749, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
7395
Total Compounds
1631
Total Assays
5
Approved Drugs
IC50: 6570.0, KI: 884.0, EC50: 25.0, KD: 618.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5407182
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL5406146
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL523586
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL5414576
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL5398425
|
10.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAPIVASERTIB
CHEMBL2325741
|
2023 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
Source Header